The use of thermographic imaging to evaluate therapeutic response in human tumour xenograft models
View/ Open
scientific_reports_2016.pdf (730.2Kb)
Download
Publication date
2016-08-05Author
Hussain, NosheenConnah, David
Ugail, Hassan
Cooper, Patricia A.
Falconer, Robert A.
Patterson, Laurence H.
Shnyder, Steven
Keyword
Experimental chemotherapyExperimental chemotherapy
Subcutaneous tumour models
Preclinical cancer pharmacology
Vascular disrupting agents
Thermographic imaging
Rights
© 2016 Macmillan Publishers Limited. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/Peer-Reviewed
YesOpen Access status
openAccess
Metadata
Show full item recordAbstract
Non-invasive methods to monitor tumour growth are an important goal in cancer drug development. Thermographic imaging systems offer potential in this area, since a change in temperature is known to be induced due to changes within the tumour microenvironment. This study demonstrates that this imaging modality can be applied to a broad range of tumour xenografts and also, for the first time, the methodology’s suitability to assess anti-cancer agent efficacy. Mice bearing subcutaneously implanted H460 lung cancer xenografts were treated with a novel vascular disrupting agent, ICT-2552, and the cytotoxin doxorubicin. The effects on tumour temperature were assessed using thermographic imaging over the first 6 hours post-administration and subsequently a further 7 days. For ICT-2552 a significant initial temperature drop was observed, whilst for both agents a significant temperature drop was seen compared to controls over the longer time period. Thus thermographic imaging can detect functional differences (manifesting as temperature reductions) in the tumour response to these anti-cancer agents compared to controls. Importantly, these effects can be detected in the first few hours following treatment and therefore the tumour is observable non-invasively. As discussed, this technique will have considerable 3Rs benefits in terms of reduction and refinement of animal use.Version
Published versionCitation
Hussain N, Connah D, Ugail H et al (2016) The use of thermographic imaging to evaluate therapeutic response in human tumour xenograft models. Scientific Reports. 6.Link to Version of Record
https://doi.org/10.1038/srep31136Type
Articleae974a485f413a2113503eed53cd6c53
https://doi.org/10.1038/srep31136